Literature DB >> 10875536

Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption.

K Morimoto1, H Katsumata, T Yabuta, K Iwanaga, M Kakemi, Y Tabata, Y Ikada.   

Abstract

The use of negatively and positively charged gelatin microspheres for pulmonary delivery of salmon calcitonin was examined in rats. The microspheres were prepared using acidic gelatin (isoelectric point (IEP):, 5.0) and basic gelatin (IEP, 9.0) for the negatively and positively charged microspheres, respectively. The average diameters of positively charged gelatin microspheres in the dry state were 3.4, 11.2, 22.5 and 71.5 microm, and that of negatively charged gelatin microspheres was 10.9 microm. Neither positively nor negatively charged gelatin microspheres underwent any degradation in pH 7.0 PBS and there was less than 8% degradation in bronchoalveolar lavage fluid (BALF) after 8 h. In in-vitro release studies in pH 7.0 PBS, salmon calcitonin was rapidly released from positively charged gelatin microspheres within 2 h, and its cumulative release was approximately 85%. In addition, the release profiles were not influenced by particle sizes. The release rates of salmon calcitonin from negatively charged gelatin microspheres were lower than that from positively charged gelatin microspheres. The cumulative release was approximately 40% after 2 h, but there was no evidence of any sustained release. The pulmonary absorption of salmon calcitonin from gelatin microspheres was estimated by measuring its hypocalcaemic effect in rats. The pharmacological availability after administration of salmon calcitonin in positively and negatively charged gelatin microspheres was significantly higher than that in pH 7.0 PBS. The pharmacological availability after administration of salmon calcitonin in positively charged gelatin microspheres was significantly higher than that in negatively charged gelatin microspheres. Administration of salmon calcitonin in positively charged gelatin microspheres with smaller particle sizes led to a higher pharmacological availability. The pharmacological availability after pulmonary administration of salmon calcitonin in positively charged gelatin microspheres with particle sizes of 3.4 and 11.2 microm was approximately 50%. In conclusion, the gelatin microspheres have been shown to be a useful vehicle for pulmonary delivery of salmon calcitonin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10875536     DOI: 10.1211/0022357001774444

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

Review 1.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 2.  Liquid-liquid two-phase systems for the production of porous hydrogels and hydrogel microspheres for biomedical applications: A tutorial review.

Authors:  Donald L Elbert
Journal:  Acta Biomater       Date:  2010-07-24       Impact factor: 8.947

3.  The formation of protein concentration gradients mediated by density differences of poly(ethylene glycol) microspheres.

Authors:  Jacob L Roam; Hao Xu; Peter K Nguyen; Donald L Elbert
Journal:  Biomaterials       Date:  2010-08-16       Impact factor: 12.479

4.  Impact of Absorption and Transport on Intelligent Therapeutics and Nano-scale Delivery of Protein Therapeutic Agents.

Authors:  Nicholas A Peppas; Daniel A Carr
Journal:  Chem Eng Sci       Date:  2009-11-16       Impact factor: 4.311

5.  Buccal transmucosal delivery of calcitonin in rabbits using thin-film composites.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

Review 6.  Respirable microspheres for inhalation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy.

Authors:  Masahiro Sakagami; Peter R Byron
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 7.  Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes.

Authors:  Maliheh Ghadiri; Paul M Young; Daniela Traini
Journal:  Pharmaceutics       Date:  2019-03-11       Impact factor: 6.321

Review 8.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.